Objective To explore the current status of the literature on the clinical drug treatment research on bipolar disorder in China and the familiarity of CONSORT statement and Jadad scale issued by psychiatrists in Chinese psychiatrists. Methods Randomized controlled trials（ RCT） on bipolar disorder clinical drug research in China were searched by Computer on CNKI， Wanfang database， Medline， Web of Science， PsycINFO， Embase and other Chinese and English databases. All the papers were divided into Group A（ before 2007）， B（ 2007-2015） and C（ 2015-2017） according to the publication and update time of the Chinese Bipolar Disorder Prevention Guidance. The methodology quality of the literatures was assessed using CONSORT statement and Jadad scale. Results A total of 154 RCT papers were searched， and the RCT researches included 149 Chinese（ 96.8%）， 5 English（ 3.2%）. The evaluation result of CONSORT statements indicated that the reporting rate of subject sources， interventions， outcome indicators， statistical methods， number of subjects included， the adverse reactions and the universal significance of the search results were all higher than 90%. However， the reporting rate of sample size， the creation of random sequence and the hiding of distribution scheme， blindness， loss and compliance of subjects are all below 50%. The result of Jadad scale showed that the number of high quality literature in China was 5， accounting for 3.4%. The number of high quality literature published abroad was 3， accounting for 60%. Conclusions There is still much room for improvement in the quality of methodological quality in the literature published in the current clinical treatment research literature of bipolar disorder in China， which is evaluated by CONSORT statement and Jadad scale. The psychiatric clinical researchers know little about the CONSORT statement and the Jadad scale， and need further special training.